

DVIII (17/05/23 11:57) Idcpwv8.doc and ART.RMD HYPERTENSION

Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity

An Individual-Participant Meta-Analysis*

Running Title: Risk Threshold for Aortic Pulse Wave Velocity

De-Wei An, † Tine W. Hansen, † Lucas S. Aparicio, Babangida Chori, Qi-Fang Huang, Fang-Fei Wei, Yi-Bang Cheng, Yu-Ling Yu, Chang-Sheng Sheng, Natasza Gilis-Malinowska, José Boggia, Wiktoria Wojciechowska, Teemu J. Niiranen, Valérie Tikhonoff, Edoardo Casiglia, Krzysztof Narkiewicz, Katarzyna Stolarz-Skrzypek, Kalina Kawecka-Jaszcz, Antti M. Jula, Wen-Yi Yang, Angela J. Woodiwiss, Jan Filipovský, Ji-Guang Wang, Marek W. Rajzer, Peter Verhamme, Tim S. Nawrot, Jan A. Staessen, ‡ Yan Li, ‡

The International Database of Central Arterial Properties for Risk Stratification Investigators§

Word Counts: Whole Manuscript 7894; Abstract 250; Number: Tables 4; Figures 2; References 38

Correspondence:

Jan A. Staessen, MD, PhD, 3026-Alliance for the Promotion of Preventive Medicine, Leopoldstraat 59, BE-2800 Mechelen, Belgium

Telephone: +32-15-41-1747

+32-47-632-4928 (cell)

Facsimile: +32-15-41-4542

Email: jan.staessen@appremed.org

Twitter jasta49

1 * This article is dedicated to the memory of Prof Gavin R. Norton, MD, PhD, who passed away on 9 2 December 2022 shortly after having attended the IDCARS Consortium Meeting (Mechelen, Belgium, 3 1-3 December 2022) and whose comprehensive understanding of arterial physiology inspired all 4 authors of this paper. 5 † Joint first authors who contributed equally. 6 ‡ Joint senior and co-corresponding authors who contributed equally. 7 § The International Database of Central Arterial Properties for Risk Stratification Investigators are 8 listed in reference 21. 9 **Affiliations** 10 Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai 11 Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Centre for 12 Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 13 China (D.-W.A., Q.-F.H., Y. B.C., C. S.S., J. G.W., Y.L.); Non-Profit Research Association Alliance for 14 the Promotion of Preventive Medicine, Belgium (D.-W.A, T.W.H, B.C., Y.-L.Y., J.A.S.); Research Unit 15 Environment and Health, Department of Public Health and Primary Care, University of Leuven, 16 Leuven, Belgium (D.-W.A, Y.-L.Y., T.S.N.); The Steno Diabetes Center Copenhagen, Herlev, and 17 Center for Health, Capital Region of Denmark, Copenhagen, Denmark (T.W.H.); Servicio de Clínica 18 Médica, Sección Hipertensión Arterial, Hospital Italiano de Buenos Aires, Argentina (L.S.A.); Centre 19 for Environmental Sciences, Hasselt University, Hasselt, Belgium (B.C., T.S.N.); Department of 20 Internal Medicine, Faculty of Clinical Sciences, College of Health Sciences, University of Abuja, Abuja, 21 Nigeria (B.C.); Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, 22 Guangzhou, China (F.-F.W.); Hypertension Unit, Department of Hypertension and Diabetology, 23 Medical University of Gdańsk, Poland (N.G.-M., K.N.); Centro de Nefrología and Departamento de 24 Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay (J.B.); First 25 Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University 26 Medical College, Kraków, Poland (W.W., K.S.-S., M.R., K.K.-J); Department of Chronic Disease 27 Prevention, Finnish Institute for Health and Welfare, Turku, Finland (T.J.N., A.M.J.); Department of 28 Medicine, Turku University Hospital and University of Turku, Turku, Finland (T.J.N., A.M.J.); 29 Department of Medicine, University of Padova, Padova, Italy (V.T., E.C.); Department of Cardiology, Shanghai General Hospital, Shanghai, China (W.-Y.Y.); School of Physiology, University of the 30 31 Witwatersrand, Johannesburg, South Africa (A.W.); Faculty of Medicine, Charles University, Pilsen, 32 Czech Republic (J.F.); Center for Molecular and Vascular Biology, KU Leuven Department of 33 Cardiovascular Sciences, University of Leuven, Leuven, Belgium (P.V.); Biomedical Science Group,

Faculty of Medicine, University of Leuven, Leuven, Belgium (J.A.S.).

34

Risk Threshold for Aortic Pulse Wave Velocity - 3 - /R1

Correspondence:
Prof Jan A. Staessen, Research Association Alliance for the Promotion of Preventive Medicine,
Leopoldstraat 59, BE-2800 Mechelen, Belgium.
Email: jan.staessen@appremed.org,
Prof Yan Li, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 192 Ruijin Er Road, Shanghai, 2000025, China. Email: liyanshcn@163.com

ABSTRACT

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

BACKGROUND: Aortic pulse wave velocity (PWV) predicts cardiovascular events (CVE) and total mortality (TM), but previous studies proposing actionable PWV thresholds have limited generalizability. This individual-participant meta-analysis is aimed at defining, testing calibration, and validating an outcome-driven threshold for PWV, using two populations studies, respectively, for derivation (IDCARS) and replication (MONICA). METHODS: A risk-carrying PWV threshold for CVE and TM was defined by multivariable Cox regression, using stepwise increasing PWV thresholds and by determining the threshold yielding a 5-year risk equivalent with systolic blood pressure of 140 mmHg. The predictive performance of the PWV threshold was assessed by computing the integrated discrimination improvement (IDI) and the net reclassification improvement (NRI). **RESULTS:** In well-calibrated models in IDCARS, the risk-carrying PWV thresholds converged at 9 m/s (10 m/s considering the anatomical pulse wave travel distance). With full adjustments applied, the threshold predicted CVE (HR [CI]: 1.68 [1.15-2.45]) and TM (1.61 [1.01-2.55]) in IDCARS and in MONICA (1.40 [1.09-1.79] and 1.55 [1.23-1.95]). In IDCARS and MONICA, the predictive accuracy of the threshold for both endpoints was ~0.75. IDI was significant for TM in IDCARS and for both TM and CVE in MONICA, whereas NRI was not for any outcome. **CONCLUSIONS:** PWV integrates multiple risk factors into a single variable and might replace a large panel of traditional risk factors. Exceeding the outcome-driven PWV threshold should motivate clinicians to stringent management of risk factors, in particular hypertension, which over a person's lifetime causes stiffening of the elastic arteries as waypoint to CVE and death.

Risk Threshold for Aortic Pulse Wave Velocity - 5 - /R1

- 65 **KEY WORDS**: aortic pulse wave velocity arterial stiffness cardiovascular risk carotid-
- 66 femoral pulse wave velocity mortality

Nonstandard Abbreviations and Acronyms

67

68	APPREMED	Non-Profit Research Association "Alliance for the Promotion of
69		Preventive Medicine"
70	ВР	blood pressure
71	CI	95% confidence interval
72	cv	Cardiovascular
73	EPOGH	European Project on Genes in Hypertension
74	FLEMENGHO	Flemish Study on Environment Genes and Health Outcomes
75	HDL	high-density lipoprotein
76	HR	hazard ratio
77	IDCARS	International Database of Central Arterial Properties for Risk
78		Stratification
79	IDI	integrated discrimination improvement
80	IQR	interquartile range
81	MONICA	Monitoring of Trends and Determinants in Cardiovascular Disease
82		Health Survey – Copenhagen
83	MAP	Mean arterial pressure
84	NRI	net reclassification improvement
85	SPRINT	Systolic Blood Pressure Intervention Trial
86	PWV	aortic pulse wave velocity (carotid-femoral pulse wave velocity)
87		

INTRODUCTION

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

Over the human lifespan, aging and age-related risk factors, such as hypertension and type-2 diabetes, lead to stiffening of the central elastic arteries. Consequently, the systolic load on the arterial walls is cushioned less, a phenomenon further amplified by the early return of reflected waves in late systole, while the tensile force maintaining a continuous blood flow during diastole diminishes. 1 Aortic pulse wave velocity (PWV) is the gold standard for the non-invasive assessment of central arterial stiffness² and predicts adverse cardiovascular (CV) outcomes in a continuous manner. 1 However, in support of clinical decision making European³ and Chinese⁴ guidelines proposed a fixed risk threshold of >12 m/s, which European experts subsequently lowered to >10 m/s, considering the difference between the measured and anatomical pulse wave travel distance.2,5-7 The literature supporting the guideline-endorsed PWV thresholds²⁻⁵ consists of patient⁸⁻¹⁵ and community-based¹⁶⁻¹⁹ studies with total or CV mortality or a composite CV endpoint as outcome. In patients with end-stage kidney disease. 9-12,15 metabolic syndrome. 14 hypertension,⁸ or in patients undergoing transluminal aortic valve replacement,¹³ PWV risk thresholds ranged from 10.5 m/s¹¹ to 11.8 m/s.¹² In Japanese-Americans,¹⁶ Japanese men,²⁰ or middle-aged or elderly community-dwelling individuals,^{17,19} the PWV risk thresholds ranged from 9.0 m/s¹⁸ to 13.7 m/s.¹⁹ In a cross-sectional meta-analysis of 16,867 individuals,7 the distribution of PWV was described as function of age in various patient strata, including a subset of 1455 patients with optimal or normal blood pressure (BP) considered to mirror population-based levels. Notwithstanding the merits of the previous publications, 11-14,16-19 PWV thresholds derived in patients with advanced disease 11-13 or disturbed metabolic profile, 14 in single-center population cohorts, 16-19 in the elderly, 17 or based on the PWV distribution rather than adverse health outcomes⁷ cannot be straightforwardly extrapolated to clinical practice. In view of these potential limitations, the

current individual-participant level meta-analysis, covering a wide age range, was prospectively and specifically designed to define, test the calibration, and validate an outcome-driven threshold for PWV, using the International <u>Database of Central Arterial Properties for Risk Stratification (IDCARS)</u>²¹ as derivation dataset and the Copenhagen subset of the <u>Moni</u>toring of Trends and Determinants in <u>Cardiovascular Disease Study</u> (MONICA) for replication.²²

METHODS

Data Availability

All available data are shown within the article and the online-only Data Supplement.

Anonymized data are available from the corresponding author upon request, on condition

that an analysis plan is accompanying the request and that the principal investigators of all

cohorts approve data sharing.

Study Cohorts

The population studies included in the current meta-analysis met the principles outlined in the Helsinki declaration for investigation of human participants.²³ The IDCARS study protocols and the secondary analyses of anonymized data were approved by the competent local Institutional or National Review Boards. Anonymized data from the Copenhagen subset of the MONICA study were used for analysis. Participants gave written informed consent at recruitment and renewed consent at each follow-up visit. The online only Data Supplement provides full details on the selection of the study population and the methods applied for collecting the clinical, biochemical and hemodynamic measurements and the statistical analysis.

IDCARS — Derivation Cohort

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

IDCARS cohorts qualified for inclusion in the present analysis, if peripheral and central BP and CV risk factors had been measured at baseline, and if follow-up included both fatal and nonfatal outcomes. Eight cohorts met these eligibility criteria (Table S1). Initial enrollment took place from 1985 until 2015. For the present analysis, baseline refers to the first measurement of central and peripheral BP along with CV risk factors (October 2000 until February 2016). Across studies, the last follow-up took place from October 2012 to December 2018 (Table S1). In the 8 qualifying IDCARS cohorts, 6546 individuals took part in a re-examination including also the vascular examination. Of those, 2706 (41.3%) only underwent a tonometric pulse wave analysis or had a substandard assessment of PWV. Of the remaining 3840 participants, 462 (12.0%) were discarded, because they were younger than 30 years, leaving 3378 IDCARS participants for statistical analysis. MONICA — Replication Cohort In 1982-1984, a random sample of the residents of Glostrup County, one of the Western suburbs of Copenhagen, Denmark was drawn with the goal to recruit an equal number of women and men aged 30, 40, 50, and 60 years. In 1993-1994, the 3785 former participants were invited for a follow-up examination at the Research Center for Prevention and Health in Glostrup, of whom 2493 (65.9%) without history of CV disease between recruitment and follow-up were examined.²² For the current analysis, 35 (1.40%) were excluded because of inaccurate or missing PWV measurements, leaving 2458 participants for analysis. **BP and PWV Measurement** In IDCARS, brachial BP was the average of the first 2 consecutive readings. Mean arterial pressure (MAP) was peripheral diastolic BP plus one-third of pulse pressure. In all IDCARS cohorts included in the current analysis, PWV was measured by sequential electrocardiographically gated recordings of the arterial pressure waveform at the carotid and femoral arteries. The observers measured the distance from the suprasternal notch to the carotid sampling site (distance A), and from the suprasternal notch to the femoral sampling site (distance B). Pulse wave travel distance was calculated as distance B minus distance A. 21 Pulse transit time was the average of 10 consecutive beats. 21 PWV is the ratio of the travel distance in meters to transit time in seconds. PWV measurements were discarded if the standard error of the mean of 10 beats was more than 10%.21 In MONICA, a trained nurse obtained 2 consecutive BP readings with a random zero mercury sphygmomanometer, which were averaged for analysis. Immediately thereafter, the same trained nurse used 2 piezoelectric pressure transducers (Hellige GmbH. Freiburg im Breisgau, Germany) to record the arterial wave simultaneously at the left common carotid and femoral arteries. 24 PWV was the travel distance between the 2 transducers, measured on the body surface, divided by the transit time, determined manually by the foot-to-foot velocity method.²⁴ For analysis, PWV measurements from 2 to 15 heart cycles were averaged. The directly measured path length (MONICA) was converted to the subtracted path length (IDCARS) in analyses involving both cohorts.^{7,25} For comparison of IDCARS and MONICA data in normal participants with a published meta-analysis, path length was converted to the path length considered to reflect the true anatomical distance, using published formula.⁷ The biochemical methods are available in the online-only Data Supplement (**p S5**).

Ascertainment of Endpoint

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

The co-primary endpoints in the current study were a composite CV endpoint, including CV death and nonfatal CV events, and total mortality. The secondary endpoints included CV mortality and fatal combined with nonfatal coronary events are defined in the Data

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

Supplement (pp **S5-S6**). In all outcome analyses, only the first event within each category was considered. Participants free of events were censored at last follow-up. Statistical Analysis Statistical methods are described in detail in the online-only Data Supplement (pp S6-S9). In exploratory analyses, incidence rates of endpoints were tabulated by tertiles of the PWV distribution, while applying the direct method for standardizing rates in IDCARS for cohort, sex and age (<40, 40-59, ≥60 years) and for sex and age group (40, 50, 60, and 70 years) in MONICA. The cumulative incidence of the primary and secondary endpoints was plotted. while accounting for cohort (in IDCARS only) and sex and age (IDCARS) or age group (MONICA). Multivariable-adjusted Cox models accounted for sex, age (IDCARS) or age group (MONICA), MAP, heart rate, body mass index, the total-to-HDL serum cholesterol ratio, smoking and drinking, use of antihypertensive drugs, history of diabetes mellitus, ²⁶ and previous CV disease (IDCARS only). Multivariable analyses involving IDCARS additionally accounted for cohort. The proportional hazards assumption was checked by the Kolmogorov-type supremum test. To compare relative risk across strata, deviation from mean coding²⁷ was applied. To determine an operational threshold for PWV, a two-pronged strategy^{28,29} was applied using Cox regression in IDCARS. First, multivariable-adjusted HRs were computed for 0.1 m/s increments in PWV from the 10th to the 90th percentile of the PWV distribution. These HRs expressed the risk in participants, whose PWV exceeded the cut-off point vs the average risk in the whole population. The HRs with CIs were plotted as function of increasing PWV thresholds to assess at which PWV level the lower 95% confidence limit of the HRs crossed unity, signifying increased risk.²⁸ Next, PWV thresholds were obtained by

determining the PWV levels yielding a 5-year risk equivalent to the risk associated with an office systolic BP of 120-, 130-, 140- and 160 mm Hg.²⁹ Model calibration was evaluated by comparing the predicted risk against overoptimism-corrected Kaplan-Meier estimates in PWV quintiles. The performance of PWV in risk stratification was assessed from 2-by-2 tables providing specificity, sensitivity and related statistics, the area under the curve, and by the integrated discrimination improvement (IDI) and the net reclassification improvement (NRI).³⁰ Finally, subgroup analyses were conducted in participants stratified by sex, age (<60 $vs \ge$ 60 years), and the approximate median systolic BP in IDCARS and MONICA (<130 $vs \ge$ 130 mm Hg).

RESULTS

Baseline Characteristics

In IDCARS, the number of interpolated values amounted to 108 (3.2%) for total serum cholesterol, 198 (5.9%) for HDL cholesterol, 89 (2.6%) for blood glucose, 161 (4.8%) for smoking and 723 (21.4%) for use of alcohol. In MONICA, the corresponding number of interpolated values were 1 (0.04%), 1 (0.04%), 5 (0.20%), 0 (0%), and 49 (1.99%), respectively.

The differences in the baseline characteristics between the IDCARS (2000-2016) and the MONICA (1993-1994) participants at the time of the vascular examinations (**Table 1**) reflect how lifestyle and treatment rates of hypertension changed over time, the ethnic make-up and the age structure of the discovery and replication cohorts, and the high tax rates levels levied on alcoholic beverages in Denmark. In both IDCARS and MONICA, women compared with men had smaller body height, lower body weight and body mass index, lower systolic and diastolic BP and MAP, and higher HDL cholesterol (**Table S2**). Across the IDCARS cohorts,

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

mean PWV (SD) ranged from 7.2 (1.5) m/s in the Polish Gdańsk cohort to 8.9 (2.4) m/s in the participants recruited in Buenos Aires, Argentina (Figure S1). In the Copenhagen MONICA cohort, PWV averaged 8.0 (2.5) m/s (Figure S1). To assess concordance between the data resources used, normal individuals were sampled from IDCARS and MONICA by excluding patients with a history of CV disease, diabetes or treated hypertension and by discarding patients with dyslipidemia and smokers (**Figure S2**). With standardization of the travel path applied, PWV by age group was largely similar in IDCARS and MONICA (Table S3). Furthermore, in single regression, the main correlates of PWV were age, systolic BP, pulse pressure and MAP (Table S4) with Pearson correlation coefficients amounting to were 0.57, 0.45, 0.43 and 0.33 in IDCARS and to 0.55, 0.53, 0.48 and 0.47 in MONICA (P<0.001 for all). **Incidence of Endpoints** Median follow-up of IDCARS participants amounted to 4.3 years (IQR: 3.8-6.9 years; 5th-95th percentile interval: 2.1-11.6 years. Over follow-up (**Table S5**), 105 participants (3.11%) died: 25 (0.74%) because of CV disease, 74 (2.19%) because of a non-CV illness (including kidney failure), and 6 (0.18%) because of non-documented illnesses. The number of IDCARS participants experiencing a major CV event or a coronary endpoint amounted to 155 (4.59%) and 77 (2.28%), respectively. Median follow-up in MONICA was 12.6 years (IQR: 12.2-13.1 years; 5th to 95th percentile interval: 3.5-13.4 years). Over this time period (**Table S5**), 393 (16.0%) died: 139 (5.66%) because of CV disease and 254 (10.3%) because of a non-CV ailment. The number of MONICA participants experiencing a major CV event, or a coronary endpoint amounted to 354 (14.4%) and 202 (8.22%), respectively. Across tertiles of the PWV distribution, in

IDCARS as well as in MONICA, the co-primary (**Table S6**) and secondary (**Table S7**) endpoints steeply increased with higher PWV category (*P*<0.001).

PWV Thresholds in IDCARS

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

Multivariable-adjusted HRs were plotted against PWV thresholds stepwise increasing by 0.1-m/s over the 10th-90th percentile range of the PWV distribution (Figure 1A and Figure **1B**). These multivariable-adjusted HRs expressed the 5-year risks of the co-primary endpoints associated with successively increasing PWV thresholds compared to the average risk in the whole IDCARS cohort. The lower limit of the 95% CI of the HRs crossed unity at a PWV level of 8.7 m/s for the composite CV endpoint and at 8.8 m/s for total mortality. In multivariable-adjusted Cox models (Figure 1C and Figure 1D), the PWV thresholds yielding a risk equivalent with a systolic BP of 140 mm Hg were 8.5 m/s (CI: 7.5-9.6) for the composite CV endpoint and 8.2 m/s (7.1-9.4) for total mortality. In all models PWV met the proportional hazard assumption (test statistic ≤ 1.26 ; $P \geq 0.175$). In IDCARS, with adjustments applied for cohort, sex, age and MAP, a PWV threshold of <9 m/s vs ≥9 m/s separated (Figure S3) the cumulative incidence of the co-primary and secondary endpoints in a highly significantly way ($P \le 0.013$). The fully adjusted HRs associated with a PWV ≥ 9 m/s vs < 9m/s, were 1.68 (CI: 1.15-2.45) for the composite CV endpoint and 1.61 (1.01-2.55) for total mortality (Table 2); for CV mortality and coronary endpoints (Table S8), the corresponding HRs were 3.21 (1.06- 9.69) and 2.08 (1.21-3.59), respectively. In **Table 2** and **Table S8**, the HRs associated with a 1-SD PWV increment were also presented allowing comparison with the literature. The fully adjusted Cox models including the 9-m/s PWV threshold were well calibrated as evidenced by similarity between the Kaplan-Meier estimates and the multivariable-adjusted mean predicted risk for the CV endpoint (P=0.654) and total mortality (P=0.691) across guintiles of observed and predicted risk (Figure 1E and Figure 1F). In

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

Rescaling of the PWV Threshold

subgroup analyses stratified for sex, age or median systolic BP, none of the interactions between the 9-m/s threshold and stratification groups reached significance (Figure S4). Replication in MONICA The MONICA data were interrogated to replicate the clinical relevance of the proposed 9-m/s threshold. In line with the IDCARS findings, with adjustments applied for sex, age group and MAP, a PWV threshold of <9 m/s vs ≥9 m/s differentiated (Figure S5) the cumulative incidence of the co-primary and secondary endpoints in a significant manner (P≤0.001), except for coronary event (P=0.145). The fully adjusted HRs associated with a PWV ≥9 m/s vs <9 m/s, were 1.40 (1.09-1.79) for the CV endpoint and 1.55 (1.23-1.95) for total mortality (**Table 2**); for CV mortality (**Table S8**) the HR was 1.53 (1.04-2.25), and for coronary events it was not significant (P=0.553). In subgroup analyses stratified for sex, age or median systolic BP, none of the interactions between the 9-m/s threshold and the stratification groups reached significance (Figure S4). **Predictive Performance** In IDCARS, specificity, sensitivity and overall accuracy of the categorized PWV for the prediction of the CV endpoint were 0.775, 0.607 and 0.769 and for the prediction of death 0.767, 0.571 and 0.764, respectively. Estimates in MONICA were of similar magnitude (Table 3). In IDCARS, IDI for the 9-m/s PWV threshold amounted to 0.59% for the CV endpoint (P=0.020) and to 0.28% (P=0.198) for total mortality, while in MONICA the corresponding IDI values were 0.47 (P=0.028) and 0.85 (P=0.002), respectively (**Table 4**). However, none of the NRI estimates in IDCARS or MONICA reached statistical significance (*P*≥0.108).

In the analysis of the IDCARS and Copenhagen MONICA data the pulse wave travel distance was standardized to the subtraction method, as applied in IDCARS. To keep consistency with current guidelines and the software presently implemented in devices for PWV measurement, the 9-m/s threshold derived in IDCARS and replicated in MONICA was rescaled to account for the difference between the measured and anatomical pulse wave travel path. With this adjustment applied the 9-m/s threshold corresponded with 10 m/s (Figure 2).

DISCUSSION

In IDCARS a two-pronged approach was applied to determine outcome-driven PWV thresholds in relation to the CV endpoint and total mortality. The PWV thresholds in well calibrated models converged to 9 m/s, of which the prognostic value was replicated in MONICA. The 2007 European Guideline for the Management of Hypertension³ proposed a risk-carrying PWV threshold of 12 m/s, because this level was believed to represent a rough estimate of high CV risk. The 2012 Consensus Document on the Measurement of PWV2 referred to the longitudinal patient and population studies published at that time to justify the 12-m/s threshold. However, the document² went on stating that the 12-m/s cut-off limit was based on the direct measurement of the pulse transit distance. It therefore proposed a new standard distance, i.e., (common carotid artery – common femoral artery) × 0.8).⁶ Applying the new standard⁶ would result in a PWV threshold of 9.6 m/s, which was rounded to 10 m/s as an easy to remember value for use in daily clinical practice.² In the current study, where relevant, the directly measured travel distance (MONICA) was converted to the subtraction distance (IDCARS)^{2,7} to increase comparability of the PWV estimates, either as descriptive variable (**Figure S1**) or as exposure variable. Accounting for the anatomical pulse wave

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

travel distance showed that the 9-m/s threshold was equivalent with the 10-m/s cut-off, as proposed in the European guidelines.^{3,7} Several results presented in the current manuscript were generated as validation of the data resources being used. First, the sex distribution of anthropometric and hemodynamic characteristics and serum lipids was in line with the literature. In both IDCARS and MONICA, women compared with men had smaller body height, lower body weight and body mass index, lower systolic and diastolic BP and MAP, and higher HDL cholesterol (Table S2). Second, the main correlates of PWV were age, systolic BP, pulse pressure and MAP (Table **S4**). Third, to assess concordance with the literature, normal individuals were sampled from the IDCARS and the MONICA cohorts, using the same exclusion criteria as described by The Reference Values for Arterial Stiffness' Collaboration (Figure S2).7 With standardization of the pulse wave travel path applied,^{2,7} PWV by age group was largely similar in IDCARS and MONICA and in agreement with the normal subgroup in the previously published cross-sectional meta-analysis (**Table S3**). Clinical Significance Modelling time-to-event using proportional hazard regression implies that the association between adverse health outcomes and a risk factor is log-linear without a threshold at which the risk suddenly increases. Population studies of office³¹ or out-of-office³² BP or serum cholesterol³³ have unmistakably illustrated this concept. Given that in the present analysis, the proportional hazard assumption for PWV was met, this construct is also applicable to PWV. For this reason, throughout the current manuscript, the risk with PWV was not only tabulated for the 9-m/s threshold, but also for a 1-SD increment in the continuously distributed PWV. Notwithstanding the continuous associations between adverse health

outcomes and risk factors, operational or actionable thresholds of risk factors support

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

clinicians in risk stratification and in identifying the need to start pharmacological treatment. Both in IDCARS and MONICA (Table 3), specificity of the 9-m/s threshold for the co-primary endpoints was ~0.80, sensitivity was ~0.55, and the overall predictive accuracy close to 0.75. IDI was significant for the CV endpoint in IDCARS and both co-primary endpoints in MONICA, whereas NRI did not reach statistical significance. The multivariable-adjusted IDI and NRI provide complementary information. Indeed, if addition of a marker to a model including several risk factors increases the predicted probability of an endpoint, this is reflected by a significant increase in IDI (Table 4). NRI indicates the extent to which a biomarker improves diagnostic accuracy, which in the current analyses was not significant, indicating that the discriminatory performance of PWV on top of commonly measured risk factors, in particular sex, age, various BP indexes (Table S4) and dyslipidemia, is small. A risk calculator is made available as Data Supplement 2. The SPARTE Investigators³⁴ and the pathophysiology of aortic stiffness³⁵⁻³⁷ provide the interpretation of these findings. Aortic stiffness, as captured by PWV, integrates the lifetime injury to the arterial wall. Elastin and collagen are the major constituents of the extracellular matrix in the media of the central elastic arteries. Elastin provides reversible extensibility during systole, while collagen generates tensile strength. As people age, the elastin fibers become fragmented and the mechanical load is transferred to collagen fibers, which are up to 1000 times stiffer than elastin.³⁵ This process already starts in young adulthood, but the deposition of elastin by vascular smooth muscle cells only occurs during fetal development and in early infancy, and is switched-off thereafter.³⁶ This implies that elastin fiber damage is basically irreversible.³⁷ In the SPARTE Trial, 34 hypertensive patients were randomized to a therapeutic strategy targeting the normalization of PWV, measured every 6 months (N=264) or to a therapeutic strategy only implementing the European Hypertension Guidelines³ (N=272). After a median follow-up of 48.3 months, there was no significant between-group difference in the primary

outcome, a composite CV endpoint (HR: 0.74; CI: 0.40-1.38). However, the secondary endpoints were met by showing that PWV-driven treatment for hypertension reduces office and ambulatory BP and aortic stiffening more than with application of BP-based guidelines. In a subgroup of 337 participants enrolled in the Systolic Blood Pressure Intervention Trial (SPRINT; 45% women; mean age: 64 years),³⁸ intensive treatment (target systolic BP <120 mm Hg) compared with usual treatment (<140 mm Hg) produced a mean between-group reduction in systolic BP of 12.7 mm Hg (CI: 11.1-14.3 mm Hg) and at the end of the 18-month follow-up had attenuated the increase in PWV (9.0 vs 10 m/s; P<0.001). Basically, both trials highlighted the pathophysiological concept, that age and high BP are the main drivers of aortic stiffening. However, clinicians should be particularly concerned about patients, in whom there is disparity between PWV, age and MAP, and retrace the previous and current medical history of such patients to identify hidden risk factors. In the context of the current study, a PWV risk threshold of 9 m/s (or 10 m/s with the correction for the anatomical pulse wave travel path applied) should motivate clinicians to achieve stringent control of BP, in particular systolic BP, the extending force to be buffered by the elastin fibers.

Limitations

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

The current study should be carefully interpreted within the context of its limitations. First, the diagnostic criteria and invasive management of coronary heart disease improved drastically from the early 1990s to the current state of the art. In MONICA only a single case of coronary revascularization was registered, whereas this number in IDCARS was 57 (**Table S5**). These period effects might explain why the 9-m/s PWV threshold was not replicated for coronary endpoints in MONICA, whereas PWV analyzed as continuously distributed variable retained significance (**Table S8**). Second, as shown by the NRI, the incremental value

Risk Threshold for Aortic Pulse Wave Velocity - 20 - /R1

associated with PWV on top of all other risk factors was not significant (**Table 4**), explaining why the NRI results were not graphically translated into an analysis of the area under the curve of nested models. Finally, although IDCARS was a multi-ethnic cohort, Blacks were not represented in the current data resource.

Perspectives

This individual-participants meta-analysis of longitudinal population studies with a composite CV endpoint and total mortality as co-primary endpoints identified, validated and replicated 9 m/s as new outcome-driven threshold for aortic PWV. With correction for the anatomical travel path, this cut-off corresponds with the 10-m/s threshold proposed in European guidelines.^{3,7} In quantitative terms, these outcome-driven thresholds refine risk stratification (IDI), albeit with a nonsignificant amount (NRI). In settings where PWV measurement can be implemented, exceeding the actionable thresholds should motivate clinicians to stringent management of modifiable CV risk factors, in particular systolic BP, which over a person's lifetime leads to elastin fragmentation in the wall of the central arteries, thereby causing major CV complication and premature mortality.

ARTICLE INFORMATION

411

412 Sources of funding 413 The Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, 414 Belgium (www.appremed.org) received a nonbinding grant from OMRON Healthcare Co. Ltd., Kyoto, 415 Japan, which supports the scholarships of D.-W.A, B.C., and Y.-L.Y. 416 The grants which supported the cohort studies are listed by country. 417 Argentina: The Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 418 Belgium: European Union (HEALTH-F7-305507 HOMAGE), European Research Council (Advanced 419 Researcher Grant 2011-294713-EPLORE and Proof-of-Concept Grant 713601-uPROPHET). 420 European Research Area Net for Cardiovascular Diseases (JTC2017-046-PROACT), and Research 421 Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium (G.0881.13); 422 China: The National Natural Science Foundation of China (grants 82270469, 82070432 and 423 82070435), the Ministry of Science and Technology (2018YFC1704902), Beijing, China, and by 424 Shanghai Municipal Health Commission (2022LJ022 and 2017BR025); 425 Czech Republic: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) 426 and Charles University Research program "Cooperatio – Cardiovascular Science". 427 Denmark: 01-2-9-9A-22914 from the Danish Heart Foundation and R32-A2740 from the Lundbeck 428 Fonden. 429 Finland: Academy of Finland (grant 321351), Emil Aaltonen Foundation, the Paavo Nurmi Foundation, 430 the Urmas Pekkala Foundation, and the Hospital District of South-Western Finland; 431 Italy: European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550); 432 Poland (Gdańsk): European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550); 433 Poland (Kraków): European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550) 434 and Foundation for Polish Science.

Risk Threshold for Aortic Pulse Wave Velocity - 22 - /R1

435

436 Disclosures

437 None.

438

439 Supplemental Material

440 Expanded Methods

441 Tables S1-S8

442 Figure S1-S5

443

REFERENCES

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

Hypertens. 2011; 29:1577-1582.

Chirinos JA, Segers P, Hughes T, Townsend R. Large-artery stiffness in health and disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 74:1237-1263. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, 2 Filipovsky J. Huybrechts S. Mattace-Raso FU. Protogerou AD, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012; 30:445-448. 3 Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. 2007 ESH-ESC practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007; 25:1751-1762. Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and 4 treatment of hypertension — A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2022; 16:182-241. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, 5 Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39:3021-3104. Huybrechts SAM, Devos DG, Vermeersch SJ, Mahieu D, Achten E, de Backer TLM, Segers P, Van Bortel LM. Carotid to femoral pulse wave velocity: a comparison of real travelled aortic path lengths determined by MRI and superficial measurements. J

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

The Reference Values for Arterial Stiffness' collaboration. Determinants of pulse wave velocity in healthy people and the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010; 31:2338-2350. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a 8 marker of cardiovascular risk in hypertensive patients. Hypertension. 1999; 33:1111-1117. 9 London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001; 38:434-438. 10 Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit arteries. Prognostic significance for end-stage renal disease patients. Hypertension. 2005; 45:592-596. 11 Adragão T, Pires A, Birne R, Dias Curto J, Lucas C, Gonçalves M, Pita Negrão A. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant. 2009; 24:997-1002. Avramovski P, Janakievska P, Sotiroski K, Zafirova-Ivanovska B, Sikole A. Aortic pulse 12 wave velocity is a strong predictor of all-cause and cardiovascular mortality in chronic dialysis patients. Ren Fail. 2013; 36:176-186. Broyd CJ, Patel K, Pugliese F, Chebab O, Mathur A, Baumbach A, Ozkor M, Kennon S, 13 Mullen M. Pulse wave velocity can be accurately measured during transcatheter aortic calve implantation and used for post-procedure risk stratification. J Hypertens. 2019; 37:1845-1852.

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

14 Ryliškyte L, Navickas R, Šerpytis P, Puronaite R, Zupkauskiene J, Juceviciene A, Badariene J, Rimkiene MA, Ryliškiene K, Skiauteryte E, et al. Association of aortic stiffness, carotid intima-media thickness and endothelial function with cardiovascular events in metabolic syndrome subjects. *Blood Press*. 2019; 28:131-138. Zhang Q, Yin K, Zhu M, Lin X, Fang Y, Lu J, Li Z, Ni Z. Combining pulse wave velocity 15 with galectin-3 to predict mortality and cerebrovascular and cardiovascular events in hemodialysis patients. Front Med. 2020; 7:579021. 16 Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, Yamane K, Kohno N. Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. Circ J. 2005; 69:259-264. 17 Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005; 111:3384-3390. 18 Inoue N, Maeda R, Kawakami H, Shokawa T, Yamamoto H, Ito C, Sasaki H. Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanse men. Circ J. 2009; 73:549-553. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp 19 Pedersen C, Olsen MH. Thresholds for pulse wave velocity, urinary albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens. 2012; 30:1928-1936.

507 Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by 20 508 indices of vascular stiffness in elderly hypertensive patients. *Hypertens Res.* 2003; 509 26:609-614. 510 Aparicio LS. Huang QF. Melgareio JD. Wei DM. Thiis L. We FF. Gilis-Malinowska N. 21 511 Sheng CS, Boggia J, Niiranen TJ, et al. The International Database of Central Arterial 512 Properties for Risk Stratification: research objectives and baseline characteristics of 513 participants. Am J Hypertens. 2021; 35:54-64. 514 22 Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the 515 516 general population. Circulation. 2006; 113:664-670. 517 23 World Medical Association. World Medical Association Declaration of Helsinki. Ethical 518 principles for medical research involving human subjects. J Am Med Assoc. 2013; 519 310:2191-2194. 520 24 Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. 521 Assessment of arterial distensibility by automatic pulse wave velocity measurement. 522 Validation and clinical application studies. *Hypertension*. 1995; 26:485-490. 523 25 Vermeersch SJ, Rietzschel ER, De Buyere ML, Van Bortel LM, Gillebert TC, Verdonck 524 PR, Laurent S, Segers P, Boutouyrie P. Distance measurements for the assessment of 525 carotid to femoral pulse wave velocity. J Hypertens. 2009; 27:2377-2385. 526 26 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the 527 Expert Committee on the diagnosis and classification of diabetes mellitus. Diabet Care. 2003; 26 (Suppl. 1):S5-S20. 528

529 Hosmer DW, Jr., Leleshow S. Applied Logistic Regression. New York, NY: John Wiley & 27 530 Sons, 1989. 531 28 Gu YM, Thijs L, Li Y, Asayama K, Boggia J, Hansen TW, Liu YP, Ohkubo T, Bjorklund-532 Bodegard K. Jeppesen J. et al. Outcome-driven thresholds for ambulatory pulse pressure 533 in 9938 participants recruited from 11 populations. Hypertension. 2014; 63:229-237. 534 29 Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart 535 T, Torp-Pedersen C, Lind L, Ibsen H, et al. Diagnostic thresholds for ambulatory blood 536 pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007; 115:2145-537 2152. 538 30 Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added 539 predictive ability of a new marker: from area under the ROC curve to reclassification and 540 beyond. Stat Med. 2008; 27:157-172. 541 31 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. 542 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of 543 individual data for one million adults in 61 prospective studies. Lancet. 2002; 360:1903-544 1913. 545 32 Li Y, Thijs L, Zhang ZY, Asayama K, Hansen TW, Boggia J, Björklund-Bodegård K, Yang 546 WY, Niiranen TJ, Ntineri A, et al. Opposing age-related trends in absolute and relative 547 risk of adverse health outcomes associated with out-of-office blood pressure. 548 Hypertension. 2019; 74:1333-1342. 549 33 Asia Pacific Cohort Studies Collaboration, Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Intern J Epidemiol. 2003; N32:563-572. 550

551 34 Laurent S, Chatellier G, Azizi M, Calvet D, Choukroun G, Danchin N, Delsart P, Girerd X, 552 Gosse P, Khettab H, et al. SPARTE Study: normalization of arterial stiffness and 553 cardiovascular events in patients with hypertension at medium to very high risk. 554 Hypertension. 2021; 78:983-995. 555 Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on 35 556 changing arterial compliance and left ventricular load in a northern Chinese urban 557 community. Circulation. 1983; 68:50-58. 558 36 Wagenseil J, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol 559 Rev. 2009; 89:957-989. 560 37 Wagenseil J, Mecham RP. Elastin in large artery stiffness and hypertension. J 561 Cardiovasc Trans Res. 2012; 5:264-273. 562 38 Upadhya B, Pajewski NM, Rocco MV, Hundley WG, Aurigemma G, Hamilton CA, Bates 563 JT, He J, Chen J, Chonchol M, et al. Effect of intensive blood pressure control on aortic 564 stiffness in the SPRINT-HEART. Hypertension. 2021; 77:1571-1580.

565

Novelty and Relevance

What is New?

566

567

- IDCARS (N=3378) and MONICA (N=2458) are large population studies assuring
- 569 generalizability.
- In well-calibrated multivariable models, the risk-carrying PWV thresholds in IDCARS
- 571 converged to 9 m/s, of which the prognostic utility was replicated in MONICA.
- The 9-m/s PWV refined risk stratification on top of classical risk factors, albeit to a minor
- 573 extent.
- Corrected for the anatomical pulse wave travel distance the 9-m/s threshold is equivalent
- 575 to 10 m/s.

576 What Are the Clinical Implications?

- Over a person's lifetime, hypertension leads to irreparable elastin fragmentation in the
- wall of elastic arteries, thereby causing major CV complications and death.
- PWV integrates all unmodifiable and modifiable risk factors in a single variable, so that its
- measurement should be encouraged for risk stratification.
- Exceeding the risk-carrying PWV threshold should motivate clinicians to stringent
- 582 management of risk factors, in particular hypertension.

FIGURE LEGENDS

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

Figure 1 Threshold and Calibration of Pulse Wave Velocity in 3378 IDCARS participants. Hazard ratios (HRs) express the risk at each PWV level relative to the average risk in the whole study population for composite cardiovascular endpoint (A) and total mortality (B) with PWV at 8.7 and 8.8 m/s signifying increased risk by crossing unity (dotted line). PWV levels yielding equivalent 5-year risks compared with systolic blood pressure categories for composite cardiovascular endpoint (C) and total mortality (D) with bars indicating 5-year risks and point and line for PWV thresholds. PWV levels at 8.5 and 8.2 m/s indicate equivalent risk as a systolic blood pressure of 140 mmHg. Model calibration for the composite cardiovascular endpoint (E) and total mortality (F), showing the predicted risk against overoptimism-corrected Kaplan-Meier estimates in PWV quintiles. All analyses were multivariable adjusted for cohort, sex, age, mean arterial pressure (excluding C and D), heart rate, the total-to-high-density lipoprotein serum cholesterol ratio, smoking and drinking, use of antihypertensive drugs, diabetes, and history of cardiovascular disease. Figure 2 Rescaling the Outcome-Driven Pulse Wave Threshold for the Anatomical Pulse Wave Travel Distance Path In the analysis of the IDCARS and the Copenhagen MONICA data the pulse wave travel distance was standardized to the subtraction method, as applied in IDCARS. To keep consistency with current guidelines and clinical practice, the 9-m/s threshold derived in IDCARS and replicated in MONICA was rescaled to account for the difference between the measured and anatomical pulse wave travel path, using the formula published in references 2 and 7. With this adjustment applied the 9-m/s threshold corresponded with 10 m/s. The gray line represents the line of identity.

Table 1. Baseline Characteristics by Cohort

Characteristic	IDCARS	MONICA	<i>P</i> -Value
Number in group	3378	2458	
Number with characteristic (%)			
Ethnicity			
Chinese	637 (18.9)	0 (0)	
White Europeans	1896 (56.1)	2458 (100)	<0.001
South Americans	845 (25)	0 (0)	
Women	1872 (55.4)	1241 (50.5)	<0.001
Hypertension	1782 (53.4)	902 (36.7)	<0.001
Treated hypertension	1221 (36.4)	203 (8.3)	<0.001
Diabetes mellitus	207 (6.1)	72 (2.9)	<0.001
History of cardiovascular disease	443 (13.2)	0 (0)	<0.001
Smokers	600 (18.7)	1319 (53.7)	<0.001
Drinkers	996 (37.5)	75 (3.1)	<0.001
Mean of characteristic (SD)			
Age, y	55.2 (14.1)	54.0 (10.6)	<0.001
Body weight, kg	71.8 (16.0)	74.7 (14.4)	<0.001
Body height, cm	165.3 (10.3)	169.5 (9.0)	<0.001
Body mass index, kg/m ²	26.1 (4.5)	25.9 (4.2)	0.17
Systolic blood pressure, mm Hg	131.4 (19.6)	129.0 (19.0)	0.001
Diastolic blood pressure, mm Hg	79.7 (10.7)	82.1 (10.6)	<0.001
Mean arterial pressure, mm Hg	96.9 (11.9)	97.7 (12.5)	0.014
Heart rate, beats per minute	68.5 (11.1)	65.9 (10.7)	<0.001
Serum total cholesterol, mmol/L	5.04 (1.00)	6.15 (1.11)	<0.001
Serum HDL cholesterol, mmol/L	1.49 (0.41)	1.45 (0.42)	0.001
Total-to-HDL cholesterol ratio	3.7 (4.2)	4.6 (1.5)	<0.001
Blood glucose, mmol/L	5.18 (0.98)	4.90 (1.08)	<0.001
Pulse wave velocity, m/s	7.95 (2.14)	8.01 (2.49)	0.29
Median follow-up (IQR), y	4.3 (3.8-6.9)	12.6 (12.2-13.1)	<0.001

Abbreviations: IDCARS, International Database of Central Arterial Properties for Risk Stratification; MONICA, Monitoring of Trends and Determinants in Cardiovascular Disease Health Study – Copenhagen; HDL, high-density lipoprotein; IQR, interquartile range.

Body mass index was weight in kilograms divided by height in meters squared. BP was the average of 2 consecutive readings. Hypertension was a BP of \geq 140 mm Hg systolic or \geq 90 mm Hg diastolic or being on antihypertensive treatment. Mean arterial pressure was diastolic BP plus one third of pulse pressure. Diabetes was a self-reported diagnosis, use of antidiabetic drugs, fasting blood glucose of \geq 7 mmol/L, random blood glucose of \geq 11.1 mmol/L, or diabetes documented in practice or hospital records. Smoking was the use of smoking materials on a daily basis. Drinking was an average alcohol intake of \geq 5 g/day.

Unit conversion factors: to convert cholesterol from mmol/L to mg/dL, multiply by 38.67; glucose from mmol/L to mg/dL, multiply by 18.

Table 2. Co-Primary Endpoints in Relation to PWV Per Threshold and Analyzed as Continuously Distributed Variable

		Model 1		Model 2		
Cohort / Endpoint	Ne/Nr	HR (95% CI)	<i>P</i> -Value	HR (95% CI)	<i>P</i> -Value	
IDCARS (discovery)						
Cardiovascular endpoint						
PWV ≥9 <i>vs</i> <9 m/s	92/807 vs 63/2571	1.76 (1.21-2.56)	0.003	1.68 (1.15-2.45)	0.007	
PWV (+1 SD)	155/3378	1.18 (1.03-1.36)	0.019	1.18 (1.02-1.36)	0.025	
Total mortality						
PWV ≥9 <i>vs</i> <9 m/s	57/807 vs 48/2571	1.75 (1.10-2.76)	0.017	1.61 (1.01-2.55)	0.045	
PWV (+1 SD)	105/3378	1.36 (1.17-1.58)	<0.001	1.32 (1.13-1.55)	<0.001	
MONICA (replication)						
Cardiovascular endpoint						
PWV ≥9 <i>vs</i> <9 m/s	160/576 vs 194/1882	1.56 (1.23-1.98)	<0.001	1.40 (1.09-1.79)	0.008	
PWV (+1 SD)	354/2458	1.27 (1.18-1.37)	<0.001	1.24 (1.14-1.34)	<0.001	
Total mortality						
PWV ≥9 <i>vs</i> <9 m/s	194/576 vs 199/1882	1.71 (1.37-2.13)	<0.001	1.55 (1.23-1.95)	<0.001	
PWV (+1 SD)	393/2458	1.26 (1.17-1.35)	<0.001	1.22 (1.13-1.32)	<0.001	

Ne/Nr indicates number of events/number of participants at risk. PWV in MONICA was standardized to the subtraction method used in IDCARS. Model 1 accounted for cohort (IDCARS only), sex, age (IDCARS) or age group (MONICA), and MAP. Model 2 additionally accounted for the total-to-HDL serum cholesterol ratio, smoking and drinking, use of antihypertensive drugs, and history of CV disease (IDCARS only).

Risk Threshold for Aortic Pulse Wave Velocity - 33 - /R1

Table 3. Discriminative Performance of Pulse Wave Velocity

625

630

Outcome	IDCARS	MONICA
Composite Cardiovascular Endpoint		
Categorized PWV (≥9 vs <9 m/s)		
N° events/at risk (%)	74/807 vs 48/2571	125/576 vs 142/1882
Specificity (95% confidence interval)	0.775 (0.760-0.789)	0.794 (0.777-0.811)
Sensitivity (95% confidence interval)	0.607 (0.514-0.694)	0.468 (0.407-0.530)
PLR (95% confidence interval)	2.694 (2.304-3.151)	2.274 (1.954-2.648)
NLR (95% confidence interval)	0.508 (0.407-0.633)	0.670 (0.597-0.751)
Accuracy	0.769 (0.754-0.783)	0.759 (0.741-0.776)
AUC (95% confidence interval)	0.691 (0.647-0.735)	0.631 (0.600-0.662)*
Continuously distributed PWV		
N° events/at risk (%)	122/3378	267/2458
AUC (95% confidence interval)	0.749 (0.705-0.793)	0.710 (0.679-0.742)
Total Mortality		
Categorized PWV (≥9 <i>vs</i> <9 m/s)		
Nº deaths/at risk (%)	36/807 vs 27/2571	136/576 vs 133/1882
Specificity (95% confidence interval)	0.767 (0.753-0.782)	0.799 (0.782-0.816)
Sensitivity (95% confidence interval)	0.571 (0.440-0.695)	0.506 (0.444-0.567)
PLR (95% confidence interval)	2.457 (1.967-3.070)	2.515 (2.176-2.907)
NLR (95% confidence interval)	0.558 (0.420-0.743)	0.619 (0.547-0.700)
Accuracy	0.764 (0.749-0.778)	0.767 (0.750-0.783)
AUC (95% confidence interval)	0.669 (0.607-0.731)	0.652 (0.621-0.683)
Continuously distributed PWV		
N° deaths/at risk (%)	63/3378	269/2458
AUC (95% confidence interval)	0.714 (0.648-0.779)	0.724 (0.693-0.756)

Calculations were performed for the 5-year risk in IDCARS and the 10-year risk in MONICA. PLR is the positive likelihood ratio (true positive rate/false positive rate. NLR is the negative likelihood ratio (false negative rate/true negative rate). Accuracy is the overall probability that an individual is correctly classified. All estimates in this table were unadjusted for other risk factors.

Significance of the AUC difference between IDCARS and MONICA: * P≤0.05

Cohort	Integrated Discrimination Improvement			Net Reclassification Improvement		
Endpoint PWV Marker	IDI (%)	95% CI (%)	<i>P</i> -value	NRI (%)	95% CI (%)	<i>P</i> -Value
IDCARS (discovery)						
Cardiovascular endpoint						
PWV ≥9 <i>vs</i> <9 m/s	0.59	(0.01, 1.83)	0.020	8.83	(-2.39, 21.0)	0.139
Continuous	0.52	(0.01, 1.74)	0.020	2.45	(-17.5, 13.4)	0.772
Total mortality						
PWV ≥9 <i>vs</i> <9 m/s	0.28	(-0.17, 1.19)	0.198	13.0	(-10.5, 25.3)	0.158
Continuous	0.90	(-0.09, 4.14)	0.079	10.5	(-7.38, 24.3)	0.317
MONICA (replication)						
Cardiovascular endpoint						
PWV ≥9 <i>vs</i> <9 m/s	0.47	(0.02, 1.41)	0.028	4.85	(-6.84, 12.13)	0.238
Continuous	1.25	(0.32, 2.44)	0.004	3.42	(-4.29, 13.03)	0.232
Total mortality						
PWV ≥9 <i>vs</i> <9 m/s	0.85	(0.19, 1.94)	0.002	6.94	(-2.51, 14.31)	0.108
Continuous	1.09	(0.30, 2.04)	0.006	0.02	(-5.98, 8.73)	0.707

Calculations were performed for the 5-year risk in IDCARS and the 10-year risk in MONICA. The base model included cohort (IDCARS only), sex, age (IDCARS) or age group (MONICA), mean arterial pressure, heart rate, body mass index, the total-to-HDL serum cholesterol ratio, smoking and drinking, diabetes and history of CV disease (IDCARS only). Pulse wave velocity (PWV) in MONICA was standardized to the subtraction method used in IDCARS. The integrated discrimination improvement (IDI) is the difference between the discrimination slopes of the base model and the base model extended by PWV. The discrimination slope is the difference in predicted probabilities (%) between participants without and with an endpoint. The net reclassification index (NRI) is the sum of the percentages of participants reclassified correctly in individuals without and with an endpoint (see Data Supplement pp **S8-S9**). IDI and NRI estimates are given with 95% CI.



